<?xml version="1.0" encoding="UTF-8"?><CAS version="2"><uima.cas.Sofa _indexed="0" _id="1" sofaNum="1" sofaID="_InitialView" mimeType="text" sofaString="P07910716A0359 Our study cohorts consisted of 15 patients who received SC rIL-2 at doses of 4.8-14.4 million IU/m2/day on 5 days per week for a total of 8 weeks, 20 patients who received rIFN-alpha 2b at 3.0-6.0 million U/m2/day thrice weekly for a total of 6 weeks, and 72 patients who were given SC rIFN-alpha 2b at 6.0 million U/m2/day thrice weekly plus SC rIL-2 at 14.4-18.0 million IU/m2/day on days 1 and 2, followed by 4.8 million IU/m2/day, 5 days per week for 6 consecutive weeks."/><uima.tcas.DocumentAnnotation _indexed="1" _id="8" _ref_sofa="1" begin="0" end="490" language="x-unspecified"/><edu.cmu.tanl.type.gene _indexed="1" _id="13" _ref_sofa="1" begin="49" end="53" Gene="rIL-2"/><edu.cmu.tanl.type.gene _indexed="1" _id="18" _ref_sofa="1" begin="140" end="151" Gene="rIFN-alpha 2b"/><edu.cmu.tanl.type.gene _indexed="1" _id="23" _ref_sofa="1" begin="233" end="244" Gene="rIFN-alpha 2b"/><edu.cmu.tanl.type.gene _indexed="1" _id="28" _ref_sofa="1" begin="283" end="287" Gene="rIL-2"/></CAS>